File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma

TitlePhase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
Authors
KeywordsBreast neoplasms
Capecitabine
Neural metastases
Temozolomide
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2006, v. 107 n. 6, p. 1348-1354 How to Cite?
AbstractBACKGROUND. A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer. METHODS. Patients were eligible if they had bidimensionally measurable supratentorial or infratentorial brain metastasis from histologically confirmed breast carcinoma. Patients could have received up to 3 prior chemotherapy regimens. Temozolomide and capecitabine were administered concomitantly to 4 sequential cohorts at different dosing levels on Days 1-5 and Days 8-12, with cycles repeated every 21 days until disease progression. RESULTS. Twenty-four patients with multiple brain lesions were treated, including 14 patients with newly diagnosed brain metastases and 10 patients with recurrent brain metastases. Only 1 patient was chemotherapy-naive. Fatigue and nausea were the most commonly observed toxicities observed at any dose levels. Significant antitumor activity was observed, with a total of 1 complete and 3 partial responses (18% objective response rate) in the brain. The median response duration was 8 weeks (range, 6-64 weeks) and the median time to progression in the brain was 12 weeks (range, 3-70 weeks). Neurocognitive function improved or remained stable in patients with a response or stable disease. CONCLUSIONS. The combination of temozolomide and capecitabine is an active, well-tolerated regimen. The observed antitumor activity warrants further evaluation of this combination as an alternative to or in combination with whole-brain radiation therapy for the treatment of multiple brain metastases. © 2006 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/146578
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRivera, Een_HK
dc.contributor.authorMeyers, Cen_HK
dc.contributor.authorGroves, Men_HK
dc.contributor.authorValero, Ven_HK
dc.contributor.authorFrancis, Den_HK
dc.contributor.authorArun, Ben_HK
dc.contributor.authorBroglio, Ken_HK
dc.contributor.authorYin, Gen_HK
dc.contributor.authorHortobagyi, GNen_HK
dc.contributor.authorBuchholz, Ten_HK
dc.date.accessioned2012-05-02T08:37:09Z-
dc.date.available2012-05-02T08:37:09Z-
dc.date.issued2006en_HK
dc.identifier.citationCancer, 2006, v. 107 n. 6, p. 1348-1354en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/146578-
dc.description.abstractBACKGROUND. A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer. METHODS. Patients were eligible if they had bidimensionally measurable supratentorial or infratentorial brain metastasis from histologically confirmed breast carcinoma. Patients could have received up to 3 prior chemotherapy regimens. Temozolomide and capecitabine were administered concomitantly to 4 sequential cohorts at different dosing levels on Days 1-5 and Days 8-12, with cycles repeated every 21 days until disease progression. RESULTS. Twenty-four patients with multiple brain lesions were treated, including 14 patients with newly diagnosed brain metastases and 10 patients with recurrent brain metastases. Only 1 patient was chemotherapy-naive. Fatigue and nausea were the most commonly observed toxicities observed at any dose levels. Significant antitumor activity was observed, with a total of 1 complete and 3 partial responses (18% objective response rate) in the brain. The median response duration was 8 weeks (range, 6-64 weeks) and the median time to progression in the brain was 12 weeks (range, 3-70 weeks). Neurocognitive function improved or remained stable in patients with a response or stable disease. CONCLUSIONS. The combination of temozolomide and capecitabine is an active, well-tolerated regimen. The observed antitumor activity warrants further evaluation of this combination as an alternative to or in combination with whole-brain radiation therapy for the treatment of multiple brain metastases. © 2006 American Cancer Society.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subjectBreast neoplasmsen_HK
dc.subjectCapecitabineen_HK
dc.subjectNeural metastasesen_HK
dc.subjectTemozolomideen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBrain Neoplasms - Drug Therapy - Secondaryen_US
dc.subject.meshBreast Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshDacarbazine - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshDeoxycytidine - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFatigue - Chemically Induceden_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil - Analogs & Derivativesen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNausea - Chemically Induceden_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVomiting - Chemically Induceden_US
dc.titlePhase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailYin, G: gyin@hku.hken_HK
dc.identifier.authorityYin, G=rp00831en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/cncr.22127en_HK
dc.identifier.pmid16909414-
dc.identifier.scopuseid_2-s2.0-33749026073en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33749026073&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume107en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1348en_HK
dc.identifier.epage1354en_HK
dc.identifier.isiWOS:000240537700019-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridRivera, E=7101648447en_HK
dc.identifier.scopusauthoridMeyers, C=7201774020en_HK
dc.identifier.scopusauthoridGroves, M=14025239600en_HK
dc.identifier.scopusauthoridValero, V=7004692933en_HK
dc.identifier.scopusauthoridFrancis, D=8575076300en_HK
dc.identifier.scopusauthoridArun, B=6603689664en_HK
dc.identifier.scopusauthoridBroglio, K=6602915196en_HK
dc.identifier.scopusauthoridYin, G=8725807500en_HK
dc.identifier.scopusauthoridHortobagyi, GN=7202399346en_HK
dc.identifier.scopusauthoridBuchholz, T=34567506600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats